Table 5. Aging marker CD56 expression in CD27− and CD28− cells in patients with polypoidal choroidal vasculopathy (PCV), patients with neovascular age-related macular degeneration (nAMD), and healthy controls.
| Patients with PCV(n = 24) | Patients with nAMD(n = 45) | Healthy controls(n = 24) | P-value | |
|---|---|---|---|---|
| CD4+ T-cells | ||||
| % CD27−CD56+, median (IQR) | 3 (1 to 12) | 3 (1 to 12) | 2 (1 to 10) | 0.93 |
| % CD28−CD56+, median (IQR) | 7 (1 to 28) | 4 (0 to 22) | 7 (0 to 24) | 0.94 |
| % CD27−CD28−CD56+, median (IQR) | 7 (0 to 27) | 8 (0 to 32) | 10 (0 to 27) | 0.97 |
| CD8+ T-cells | ||||
| % CD28−CD56+, median (IQR) | 73 (64 to 81) | 84 (69 to 88) | 76 (63 to 83) | 0.030 |
| % CD27−CD56+, median (IQR) | 72 (60 to 81) | 84 (72 to 88) | 79 (65 to 83) | 0.0057 |
| % CD28−CD27−CD56+, median (IQR) | 70 (58 to 81) | 84 (68 to 88) | 77 (64 to 83) | 0.014 |
Abbreviations: PCV = polypoidal choroidal vasculopathy; nAMD = neovascular age-related macular degeneration; IQR = interquartile range. Statistical comparisons are made using Kruskal-Wallis' test. Bold text indicates a statistically significant difference.